Arkin Holdings, Phoenix Group sign collaboration deal to invest $60m in pharma and biotech companies
The new partnership, ‘Arkin Bio-Ventures’ (51% Arkin Holdings and 49% Phoenix) aims to invest in companies that develop promising innovative pharmaceuticals in pre-clinical and more advanced stages, both
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.